Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema

被引：11
作者：
Konidaris, V. E. [1 ]
Tsaousis, K. T. [1 ]
Al-Hubeshy, Z. [1 ]
Pieri, K. [1 ]
Deane, J. [1 ]
Empeslidis, T. [1 ]
机构：
[1] Leicester Royal Infirm, Ophthalmol Dept, Leicester, Leics, England
来源：
EYE | 2017年 / 31卷 / 11期
关键词：
AND/OR BEVACIZUMAB;
D O I：
10.1038/eye.2017.122
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：1629 / 1630
页数：3
相关论文
共 3 条
  • [1] Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
    Lim, Laurence S.
    Ng, Wei Yan
    Mathur, Ranjana
    Wong, Doric
    Wong, Edmund Y. M.
    Yeo, Ian
    Cheung, Chui Ming Gemmy
    Lee, Shu Yen
    Wong, Tien Yin
    Papakostas, Thanos D.
    Kim, Leo A.
    [J]. CLINICAL OPHTHALMOLOGY, 2015, 9 : 1715 - 1718
  • [2] Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness
    Shah, Chirag P.
    Heier, Jeffrey S.
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2016, 47 (09) : 836 - 839
  • [3] Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab
    Wood, Edward H.
    Karth, Peter A.
    Moshfeghi, Darius M.
    Leng, Theodore
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (09) : 950 - 954
1